Physician profile
Kimberlynn R Richards
NPI 1760401756
$14,471.90
in general payments reported to CMS, 2019-2025
9 companies · $442 in 2025
The $442 reported for 2025 was more than what 77% of Addiction Medicine (Internal Medicine) providers received nationally (typical 2025 total: $124).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $11K · 2020: $445 · 2021: $1,780 · 2022: $268 · 2023: $321 · 2024: $249 · 2025: $442.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,013.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,012.77 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Indivior INC. | $10,918.26 | 2019-2025 | Sublocade |
| Alkermes, INC. | $1,784.88 | 2019-2025 | Vivitrol, Vivitrol |
| Novo Nordisk INC | $1,417.05 | 2019-2025 | Wegovy |
| Abbvie INC. | $247.52 | 2021-2023 | |
| Orexo US, INC. | $35.35 | 2020-2022 | |
| Allergan, INC. | $22.09 | 2019 | |
| Takeda Pharmaceuticals U.S.A., INC. | $21.88 | 2022 | |
| Biodelivery Sciences International, INC. | $12.57 | 2019 | |
| Eisai INC. | $12.30 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Kimberlynn Richards listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.